The purpose of this study was to determine the incidence and severity of @entity1415 in @entity1 treated with @entity1311 . @entity1 who were treated with @entity1311 filled a questionnaire regarding their general health, medications and incidents of @entity1415 . Relevant clinical information was obtained from the @entity1 ' charts. Forty-seven consecutive @entity1 were recruited to the study. Twenty-four (51%) of the @entity1 reported @entity1415 during @entity1311 therapy. Twenty-three of 39 (59%) @entity1 who received weekly @entity1311 had @entity1415 at least once during treatment, compared with one out of eight @entity1 who were treated every 3 weeks (P = 0.045). All episodes of @entity1415 were mild, occurred with normal platelets counts and did not require blood product transfusions or treatment modification. The majority of the @entity1 experienced the first episode of @entity1415 on the third week of weekly @entity1311 treatment and then repeatedly throughout therapy. It is concluded that @entity1415 is a common mild side-effect of weekly @entity1311 that has not been reported previously. In this trial, @entity1415 did not have any major clinical consequences. However, when @entity1311 is combined with other drugs that may cause @entity548 , such as bevacizumab, physicians should be alerted to the potential risk of this phenomenon.

Epistaxis during treatment with XXXX .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1415 :: ('MESH:D004844', 'Disease') :: ['epistaxis'] @entity1311 :: ('MESH:D017239', 'Chemical') :: ['paclitaxel'] @entity548 :: ('MESH:D006470', 'Disease') :: ['bleeding']
@entity1311 :: (MESH:D017239,Chemical) :: ['paclitaxel']
